Fig. 1 · Structure

Documents & Downloads

Evofosfamide (TH-302)

Cat. No. A11144 CAS 918633-87-1
TH-302 is a selectively targeting hypoxic regions of solid tumors hypoxia-activated prodrug.

In Stock

Publications for Evofosfamide

2 publications citing this product

  1. Anirudh Sattiraju, .et al. , Immunity, 2023, Aug 8;56(8):1825-1843 PMID: 37451265
  2. Anirudh Sattiraju, .et al. , bioRxiv, 2022, March 04

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

TH-302 (evofosfamide) is a hypoxia-activated prodrug. In a cell-free POR/NADPH system, oxygen-dependent EPR spin-adduct kinetics supported aerobic redox cycling and reductive fragmentation under hypoxia. This experiment inferred activation rather than directly measuring released Br-IPM. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
DU-145 IC50 4.14 μM Cytotoxicity against human DU145 cells incubated for 2 hrs under hypoxic condition measured after 72 hrs by Alamar blue assay [PMID: 29259746]
DU-145 IC50 842 μM Cytotoxicity against human DU145 cells incubated for 2 hrs under normoxic condition measured after 72 hrs by Alamar blue assay [PMID: 29259746]
H-EMC-SS IC50 0.13 μM Antiproliferative activity against human HEMC-SS cells treated for 24 hrs under hypoxic condition followed by compound wash-out and incubated under normoxic condition for 48 hrs by alamar blue assay [PMID: 30199705]
H-EMC-SS IC50 2.9 μM Antiproliferative activity against human HEMC-SS cells treated for 24 hrs under normoxic condition followed by compound wash-out and incubated under normoxic condition for 48 hrs by alamar blue assay [PMID: 30199705]
HT-29 IC50 > 100 μM Cytotoxicity against human HT-29 cells pretreated for 24 hrs under normoxic condition followed by compound washout measured after 72 hrs by MTT assay [PMID: 28350997]
HT-29 IC50 49.51 μM Cytotoxicity against human HT-29 cells pretreated for 24 hrs under hypoxic condition followed by compound washout measured after 72 hrs by MTT assay [PMID: 28350997]
MDA-MB-468 IC50 0.0062 μM Cytotoxicity against human MDA-MB-468 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay [PMID: 30885680]
MDA-MB-468 IC50 4.403 μM Cytotoxicity against human MDA-MB-468 cells incubated for 4 hrs under aerobic condition followed by compound washout and measured after 5 days by SRB assay [PMID: 30885680]
NCI-H460 IC50 0.019 μM Cytotoxicity against human H460 cells under hypoxic condition after 2 hrs by Alamar blue staining assay [PMID: 18257544]
NCI-H460 IC50 5.1 μM Cytotoxicity against human H460 cells under normoxic condition after 2 hrs by Alamar blue staining assay [PMID: 18257544]
NCI-H460 IC50 50.97 μM Cytotoxicity against human NCI-H460 cells pretreated for 24 hrs under normoxic condition followed by compound washout measured after 72 hrs by MTT assay [PMID: 28350997]
NCI-H460 IC50 6650 nM Cytotoxicity against human NCI-H460 cells after 24 hrs under normoxic condition by luminescence-based Cell-Titer Glo assay [PMID: 29079474]
NCI-H460 IC50 9.08 μM Cytotoxicity against human NCI-H460 cells pretreated for 24 hrs under hypoxic condition followed by compound washout measured after 72 hrs by MTT assay [PMID: 28350997]
NCI-H460 IC50 9.3 nM Cytotoxicity against human NCI-H460 cells after 24 hrs under hypoxic condition by luminescence-based Cell-Titer Glo assay [PMID: 29079474]
PC-3 IC50 6.49 μM Cytotoxicity against human PC3 cells incubated for 2 hrs under hypoxic condition measured after 72 hrs by Alamar blue assay [PMID: 29259746]
PC-3 IC50 687 μM Cytotoxicity against human PC3 cells incubated for 2 hrs under normoxic condition measured after 72 hrs by Alamar blue assay [PMID: 29259746]
SW-620 IC50 0.052 μM Cytotoxicity against human SW620 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay [PMID: 30885680]
SW-620 IC50 20.6 μM Cytotoxicity against human SW620 cells incubated for 4 hrs under aerobic condition followed by compound washout and measured after 5 days by SRB assay [PMID: 30885680]

18 records · Scroll to view more

Evofosfamide (TH-302) Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Evofosfamide (TH-302) from 3 published references.

Evofosfamide (TH-302) In Vitro Studies

TH-302 showed greater clonogenic cytotoxicity under anoxia than in air in SCCVII and HT29 cells after a 2-hour exposure. Reported concentrations at 10% survival were 50 μM versus 40 nM for SCCVII and 80 μM versus 200 nM for HT29 (air versus anoxia). These endpoints are not IC50 values. [1]

Oxygen-dependent TH-302 redox cycling in a cell-free enzyme system

Biochemical assay · Cell-free NADPH:cytochrome P450 oxidoreductase (POR)/NADPH reaction with DMPO spin trapping [1]

Oxygen-dependent EPR signals support the authors’ model of aerobic redox cycling and increased reductive fragmentation under hypoxia. Br-IPM release was inferred from spin-adduct kinetics, not directly quantified in this experiment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Oxygen-dependent DMPO-superoxide EPR spin-adduct signalQualitative EPR response Aerobic signal persisted; peak/plateau behavior changed with decreasing oxygen. Vehicle and superoxide dismutase controls were shown.[1]

Literature-Reported Treatment Conditions

Treatment concentration
TH-302 1 mM; NADPH 1 mM; POR 4.5 μg/ml; DMPO 110 mM
Exposure duration
Spectra followed for 15 min
Method
Cell-free EPR at 37°C under the indicated oxygen tensions, including air (150 mmHg) and anoxia (0 mmHg).
Vehicle
Dulbecco’s phosphate-buffered saline containing 10% DMSO
Reported limits
Exact replication for the displayed spectra is not specified in the read main-text methods/caption. No cellular dose or direct metabolite concentration is inferred.
Methods and source locations

Compound reported in the paper: TH-302 (evofosfamide); Compound label in the paper: TH-302

Results apply to the reported research material and model; no A11144 lot equivalence or salt conversion is inferred.

Figure 1A–E; Results first redox paragraph; Materials and Methods: EPR spin trapping

Oxygen-dependent DMPO-superoxide EPR spin-adduct signal: EPR spin trapping; repeated spectra over 15 min. Signal decay supports the fragmentation interpretation but is not a direct Br-IPM assay. — Figure 1B–E; Results redox-cycling paragraph

Hypoxia-selective clonogenic killing in SCCVII and HT29 cells

Cell-based study · Murine SCCVII squamous carcinoma and human HT29 colon carcinoma monolayers [1]

After a 2-hour exposure, TH-302 concentrations associated with 10% clonogenic survival were substantially lower under anoxia than in air in both models. These are survival-endpoint concentrations, not IC50 values or dosing recommendations.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
SCCVII clonogenic survival at 10% of controlConcentration at 10% survival 50 μM in air versus 40 nM under anoxia[1]
HT29 clonogenic survival at 10% of controlConcentration at 10% survival 80 μM in air versus 200 nM under anoxia[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response curves; endpoint concentrations are listed in measurements.
Exposure duration
2 h exposure, followed by 10–14 days for colony formation
Method
Clonogenic survival under air (150 mmHg oxygen) or anoxia (0 mmHg oxygen); surviving fractions evaluated relative to control.
Reported limits
A clonogenic dosing vehicle is not explicitly specified in the read cell-survival method; do not borrow 10% DMSO from the EPR assay. Methods report two to three experimental repeats, without assigning a precise n to each Figure 2A curve.
Methods and source locations

Compound reported in the paper: TH-302 (evofosfamide); Compound label in the paper: TH-302

Results apply to the reported research material and model; no A11144 lot equivalence or salt conversion is inferred.

Figure 2A–C; Results oxygen-dependent cytotoxicity paragraph; Materials and Methods: Cell survival studies

SCCVII clonogenic survival at 10% of control: Reported in Results for Figure 2A; 2 h drug exposure at 150 versus 0 mmHg oxygen, followed by colony formation for 10–14 days; colonies >50 cells scored. Values were not digitized from curves. — Figure 2A; Results oxygen-dependent cytotoxicity paragraph

HT29 clonogenic survival at 10% of control: Reported in Results for Figure 2A; 2 h drug exposure at 150 versus 0 mmHg oxygen, followed by colony formation for 10–14 days; colonies >50 cells scored. Values were not digitized from curves. — Figure 2A; Results oxygen-dependent cytotoxicity paragraph

Evofosfamide (TH-302) In Vivo Studies

In MIA PaCa-2 pancreatic xenografts, TH-302 alone had limited activity. Adding TH-302 to gemcitabine increased reported tumor growth inhibition from 48% to 87% and growth delay from 8 to 22 days, while maximal body-weight loss increased from 0.0% to 9.1%. These are combination-treatment tumor-growth results. [2]

In intracranial GL261 glioblastoma, evofosfamide reduced tumor area, while its effect on UnaG-positive hypoxia-reporter abundance was nonsignificant. Radiation plus evofosfamide reduced both readouts versus control, but neither readout differed significantly from radiation alone. The experiment does not establish improved survival or combination synergy. [3]

TH-302 with gemcitabine in MIA PaCa-2 pancreatic xenografts

Animal study · Subcutaneous human MIA PaCa-2 pancreatic carcinoma xenografts in female SCID mice; shared Animals method reports age 5–6 weeks [2]

TH-302 alone showed limited activity. Combination treatment increased tumor growth inhibition and growth delay compared with gemcitabine alone, with greater maximal body-weight loss. Tumor-growth endpoints do not establish survival benefit.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor growth inhibition relative to vehicleTGI TH-302: 21%; gemcitabine: 48% (**); combination: 87% (**, ##)[2]
Growth delay to a mean tumor volume of 500 mm³ versus vehicleTGD500 TH-302: 0 days; gemcitabine: 8 days; combination: 22 days[2]
Maximal body-weight loss relative to the first treatment dayMBL TH-302: 1.9%; gemcitabine: 0.0%; combination: 9.1%[2]

Conditions shared by the study groups

Vehicle
0.9% NaCl
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle controlVehicle; gemcitabine-alone comparator for the combinationReference for TGI and TGD500.[2]
TH-302 monotherapy
TH-302 75 mg/kg
Vehicle; gemcitabine-alone comparator for the combinationTGI 21%; TGD500 0 days; maximal body-weight loss 1.9%.[2]
Gemcitabine monotherapy
Gemcitabine 60 mg/kg
Vehicle; gemcitabine-alone comparator for the combinationTGI 48% (** versus vehicle); TGD500 8 days; maximal body-weight loss 0.0%.[2]
TH-302 plus gemcitabine
TH-302 75 mg/kg plus gemcitabine 60 mg/kg
Vehicle; gemcitabine-alone comparator for the combinationTGI 87% (p<0.01 versus vehicle and gemcitabine alone); TGD500 22 days; maximal body-weight loss 9.1%.[2]
Vehicle control
Model: Subcutaneous human MIA PaCa-2 pancreatic carcinoma xenografts in female SCID mice; shared Animals method reports age 5–6 weeks
Reported limits: MIA PaCa-2-specific group size not specified in the read main-text locations. Vehicle-control administration schedule is not separately specified.
TH-302 monotherapy
Model: Subcutaneous human MIA PaCa-2 pancreatic carcinoma xenografts in female SCID mice; shared Animals method reports age 5–6 weeks
Route: Intraperitoneal
Frequency: Every third day
Treatment course: Five doses
Reported limits: MIA PaCa-2-specific group size not specified in the read main-text locations.
Gemcitabine monotherapy
Model: Subcutaneous human MIA PaCa-2 pancreatic carcinoma xenografts in female SCID mice; shared Animals method reports age 5–6 weeks
Route: Intraperitoneal
Frequency: Every third day
Treatment course: Five doses
Reported limits: MIA PaCa-2-specific group size not specified in the read main-text locations.
TH-302 plus gemcitabine
Model: Subcutaneous human MIA PaCa-2 pancreatic carcinoma xenografts in female SCID mice; shared Animals method reports age 5–6 weeks
Route: Intraperitoneal
Frequency: Every third day
Treatment course: Five doses
Reported limits: MIA PaCa-2-specific group size not specified in the read main-text locations.
Methods and source locations

Compound reported in the paper: TH-302 (evofosfamide); Compound label in the paper: TH-302

Results apply to the reported research material and model; no A11144 lot equivalence or salt conversion is inferred.

Figure 3G and caption; Table 2 MIA PaCa-2 row and footnotes a/e/f; Results additional xenografts; Methods drug regimens, Animals and Ectopic xenograft models

Tumor growth inhibition relative to vehicle: Table 2 values; ** p<0.01 versus vehicle, ## p<0.01 versus chemotherapy monotherapy. TGI uses changes in mean tumor volume; the endpoint rule is the first tumor-size euthanasia or mean vehicle volume 1000 mm³. Dunnett’s test is specified. No SD/SEM is appended to these table values. — Table 2 MIA PaCa-2 row, headers and significance footnotes; Ectopic xenograft models

Growth delay to a mean tumor volume of 500 mm³ versus vehicle: Table 2 values; ** p<0.01 versus vehicle, ## p<0.01 versus chemotherapy monotherapy. TGI uses changes in mean tumor volume; the endpoint rule is the first tumor-size euthanasia or mean vehicle volume 1000 mm³. Dunnett’s test is specified. No SD/SEM is appended to these table values. — Table 2 MIA PaCa-2 row, headers and significance footnotes; Ectopic xenograft models

Maximal body-weight loss relative to the first treatment day: Table 2 values; ** p<0.01 versus vehicle, ## p<0.01 versus chemotherapy monotherapy. TGI uses changes in mean tumor volume; the endpoint rule is the first tumor-size euthanasia or mean vehicle volume 1000 mm³. Dunnett’s test is specified. No SD/SEM is appended to these table values. — Table 2 MIA PaCa-2 row, headers and significance footnotes; Ectopic xenograft models

Vehicle control · Figure 3G and caption; Table 2 MIA PaCa-2 row and footnotes a/e/f; Results additional xenografts; Methods drug regimens, Animals and Ectopic xenograft models

TH-302 monotherapy · Figure 3G and caption; Table 2 MIA PaCa-2 row and footnotes a/e/f; Results additional xenografts; Methods drug regimens, Animals and Ectopic xenograft models

Gemcitabine monotherapy · Figure 3G and caption; Table 2 MIA PaCa-2 row and footnotes a/e/f; Results additional xenografts; Methods drug regimens, Animals and Ectopic xenograft models

TH-302 plus gemcitabine · Figure 3G and caption; Table 2 MIA PaCa-2 row and footnotes a/e/f; Results additional xenografts; Methods drug regimens, Animals and Ectopic xenograft models

Evofosfamide and radiation in intracranial GL261 glioblastoma

Animal study · GL261-HRE-UnaG intracranial glioblastoma in C57BL/6 wild-type mice; four randomized treatment cohorts [3]

Evofosfamide reduced tumor area, but its reduction of UnaG-positive abundance was nonsignificant. The combination produced small tumors and low UnaG abundance; tumor size did not differ significantly between radiation alone and radiation plus evofosfamide.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor area after 2 weeks of treatmentRelative tumor size (a.u.) Evo versus control: *; RT versus control: **; RT+Evo versus control: **; RT+Evo versus RT: ns.[3]
UnaG-positive abundance after treatmentHypoxia-reporter-positive area (%) Evo versus control: ns; RT versus control: ***; RT+Evo versus control: ***; RT+Evo versus RT: ns.[3]
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Control cohortControl cohort; radiation-alone cohort for incremental combination effectReference tumor area and UnaG abundance; injection details unspecified.[3]
Evofosfamide alone
50 mg/kg
Control cohort; radiation-alone cohort for incremental combination effectTumor area reduced versus control (*); UnaG-positive abundance change nonsignificant.[3]
Radiation alone
2.5 Gy per fraction
Control cohort; radiation-alone cohort for incremental combination effectTumor area reduced (**); UnaG-positive abundance reduced (***), each versus control.[3]
Radiation plus evofosfamide
Evofosfamide 50 mg/kg plus radiation 2.5 Gy per fraction
Control cohort; radiation-alone cohort for incremental combination effectTumor area reduced (**) and UnaG abundance reduced (***) versus control; both comparisons with radiation alone marked ns.[3]
Control cohort
Model: GL261-HRE-UnaG intracranial glioblastoma in C57BL/6 wild-type mice; four randomized treatment cohorts
Reported limits: Evofosfamide solvent and control-injection details unspecified; n=3 mice for tumor area, n=10 sampled areas from 3 mice for UnaG abundance.
Evofosfamide alone
Model: GL261-HRE-UnaG intracranial glioblastoma in C57BL/6 wild-type mice; four randomized treatment cohorts
Route: Intraperitoneal
Frequency: Daily
Treatment course: 2 weeks
Reported limits: Evofosfamide solvent and control-injection details unspecified; n=3 mice for tumor area, n=10 sampled areas from 3 mice for UnaG abundance.
Radiation alone
Model: GL261-HRE-UnaG intracranial glioblastoma in C57BL/6 wild-type mice; four randomized treatment cohorts
Route: Head-directed irradiation
Frequency: Twice weekly
Treatment course: 2 weeks (5 Gy/week)
Reported limits: Evofosfamide solvent and control-injection details unspecified; n=3 mice for tumor area, n=10 sampled areas from 3 mice for UnaG abundance.
Radiation plus evofosfamide
Model: GL261-HRE-UnaG intracranial glioblastoma in C57BL/6 wild-type mice; four randomized treatment cohorts
Route: Intraperitoneal evofosfamide; head-directed irradiation
Frequency: Evo daily; radiation twice weekly
Treatment course: 2 weeks
Reported limits: Evofosfamide solvent and control-injection details unspecified; n=3 mice for tumor area, n=10 sampled areas from 3 mice for UnaG abundance.
Methods and source locations

Compound reported in the paper: TH-302 (evofosfamide); Compound label in the paper: Evo

Results apply to the reported research material and model; no A11144 lot equivalence or salt conversion is inferred.

Figure 4A–B and caption; Results Targeting hypoxic niches; STAR Methods Irradiation and evofosfamide treatment, Mice, Immunofluorescence and immunohistochemistry, Statistical analysis

Tumor area after 2 weeks of treatment: Figure 4B significance brackets viewed; * P<0.05, ** P<0.01; n=3 mice per group. One-way ANOVA; shared statistics specify Tukey post-hoc correction and means ± SEM. No bar-height decimals reconstructed. — Figure 4A–B; Figure 4 caption; Statistical analysis

UnaG-positive abundance after treatment: Figure 4B brackets viewed; *** P<0.001. n=10 randomly selected tumor areas from 3 mice per cohort, not 10 independent mice. One-way ANOVA; shared statistics specify Tukey post-hoc correction and means ± SEM. No percentages digitized. — Figure 4A–B and caption; Statistical analysis

Control cohort · Figure 4A–B and caption; Results Targeting hypoxic niches; STAR Methods Irradiation and evofosfamide treatment, Mice, Immunofluorescence and immunohistochemistry, Statistical analysis

Evofosfamide alone · Figure 4A–B and caption; Results Targeting hypoxic niches; STAR Methods Irradiation and evofosfamide treatment, Mice, Immunofluorescence and immunohistochemistry, Statistical analysis

Radiation alone · Figure 4A–B and caption; Results Targeting hypoxic niches; STAR Methods Irradiation and evofosfamide treatment, Mice, Immunofluorescence and immunohistochemistry, Statistical analysis

Radiation plus evofosfamide · Figure 4A–B and caption; Results Targeting hypoxic niches; STAR Methods Irradiation and evofosfamide treatment, Mice, Immunofluorescence and immunohistochemistry, Statistical analysis

Specifications

Manufacturer Adooq Bioscience
CAS Number 918633-87-1
Formula C9H16Br2N5O4P
Molecular Weight 449
Synonyms TH302
SMILES
CN1C(=CN=C1[N+](=O)[O-])COP(=O)(NCCBr)NCCBr

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 80 mg/mL (178.15 mM)
Water Warmed: 9 mg/mL (20.03 mM)
Ethanol 80 mg/mL (178.15 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% propylene glycol, 5% Tween 80, 65% D5W

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Evofosfamide (TH-302) Research References

  1. [1] Takakusagi Y, Kishimoto S, Naz S, et al. Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies Antioxidants & redox signaling (2018). PMID: 28741367 DOI: 10.1089/ars.2017.7106 Source material
  2. [2] Liu Q, Sun JD, Wang J, et al. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules Cancer chemotherapy and pharmacology (2012). PMID: 22382881 DOI: 10.1007/s00280-012-1852-8 Source material
  3. [3] Sattiraju A, Kang S, Giotti B, et al. Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression Immunity (2023). PMID: 37451265 DOI: 10.1016/j.immuni.2023.06.017 Source material

Publications

2 publications citing this product

  1. Anirudh Sattiraju, .et al. , Immunity, 2023, Aug 8;56(8):1825-1843 PMID: 37451265
  2. Anirudh Sattiraju, .et al. , bioRxiv, 2022, March 04

Added to your cart

View Cart Checkout
Loading...